Format

Send to

Choose Destination
Indian J Dermatol Venereol Leprol. 2014 Jul-Aug;80(4):296-9. doi: 10.4103/0378-6323.136831.

Factors affecting the duration of phase I of dexamethasone - cyclophosphamide pulse therapy.

Author information

1
Department of Dermatology, Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai Central, Mumbai, India.

Abstract

BACKGROUND:

The introduction of dexamethasone-cyclophosphamide pulse (DCP) therapy for the pemphigus group of disorders by Pasricha has revolutionized the therapy for pemphigus. There are very few studies regarding factors affecting duration of phase I of the DCP.

AIMS:

Our purpose was to study the relationship between various factors and duration of the phase I.

METHODS:

A retrospective study of 98 patients of pemphigus on Dexamethasone Pulse therapy was conducted. Patients were classified according to duration of Phase 1 as those with phase I less than 6 months and those more than 6 months and analyzed for variable factors affecting duration of phase I.

RESULTS:

Disease severity in pemphigus significantly prolonged the duration of phase I of DCP. Longer duration was also observed in patients on concurrent oral steroid therapy (both statistically significant).

CONCLUSION:

The findings from our study help us to address patient expectations and apprehensions regarding duration of therapy. A detailed understanding of the various patient and disease related factors responsible for affecting Phase I duration will help in better management of the patient, and the disease.

PMID:
25035352
DOI:
10.4103/0378-6323.136831
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center